Search results for "Ophthalmic Solution"

showing 10 items of 41 documents

Ocular Penetration of Topically Applied Norfloxacin 0.3% in the Rabbits and in Humans

1992

The kinetics of topically applied norfloxacin 0.3 percent were studied in rabbit and man. All measurements were performed by high-pressure liquid chromatography. Norfloxacin concentrations were investigated five to 120 minutes in rabbit ocular tissues after instillation of a single drop. In normal eyes, after 30 minutes, mean +/- SEM levels were 14.3 +/- 3.7 micrograms/g in cornea, 3.3 +/- 0.7 micrograms/g in conjunctiva, 0.2 +/- 0.1 microgram/g in aqueous humor. After removal of the corneal epithelium concentrations were as follows: 84.2 +/- 15.8 micrograms/g, 7.3 +/- 2.3 micrograms/g, 8.6 +/- 1.9 micrograms/g respectively. Penetration in posterior ocular tissues were rather poor. In human…

AdultMalemedicine.medical_specialtyConjunctivaAdolescentgenetic structures[SDV]Life Sciences [q-bio]EyeCorneaPharmacokineticsCorneaOphthalmologymedicineAnimalsHumansTissue DistributionPharmacology (medical)Chromatography High Pressure LiquidNorfloxacinAgedAntibacterial agentCorneal epitheliumAged 80 and overPharmacologyLagomorphabiologybusiness.industryPenetration (firestop)Middle Agedbiology.organism_classificationeye diseasesSurgeryOphthalmologymedicine.anatomical_structureFemaleRabbitssense organsOphthalmic SolutionsbusinessKeratoplasty PenetratingNorfloxacinmedicine.drugJournal of Ocular Pharmacology and Therapeutics
researchProduct

Patient-Reported Nonadherence with Glaucoma Therapy

2019

Abstract Purpose: Effective glaucoma therapy relies to a great extent on the patients' ability to regularly self-administer eye drops. This study aimed to assess self-reported nonadherence and to identify potential barriers to adherence in glaucoma patients. Methods: Participants completed a 16-item questionnaire, designed to examine nonadherence rate and assess the therapy experience. Inclusion criteria stipulated treatment duration of at least 1 year. Nonadherence was defined as missing ≥5% of the prescribed pressure-lowering eye drops doses. Results: In total, 201 glaucoma patients aged 24–88 years were included. Mean treatment duration was 9.4 years. Nonadherence was reported by 30.3% o…

AdultMalemedicine.medical_specialtygenetic structuresGlaucomaoutcomesYoung AdultGermanySurveys and QuestionnairesmedicineHumansPharmacology (medical)adherencePatient Reported Outcome MeasuresIntensive care medicineAntihypertensive AgentsAgedPharmacologyAged 80 and overnonadherencebusiness.industryPreservatives PharmaceuticalGlaucomaOriginal ArticlesMiddle Agedmedicine.diseaseeye diseasesOphthalmologyside effectsPatient ComplianceFemalesense organspreservativesInjections IntraocularOphthalmic SolutionsbusinessJournal of Ocular Pharmacology and Therapeutics
researchProduct

OCT for Assessing Artificial Tears Effectiveness in Contact Lens Wearers

2011

PURPOSE: To apply a commercially available high-resolution spectral domain optical coherence tomographer (SOCT) to assess the change in tear volume after application of a new artificial tears formulation specifically developed for contact lens (CL) users. METHODS: Twenty OD from young healthy CL wearers (mean age, 24.7 ± 3.5 years) with refractive errors ranging from -0.75 to -2.50 D (mean, -1.56 ± 0.69 D) were examined. All subjects were fitted with Focus Dailies CL (Ciba Vision), and two drops of Blink Contacts (AMO), lubricating formulation specifically developed for CL wearers, were instilled after baseline measures. Tear meniscus volume (TMV) was measured immediately after and 1 min, 1…

Adultmedicine.medical_specialtyContact Lensesmedicine.medical_treatmentMeniscus (anatomy)Tear volumeYoung AdultRegular distributionOphthalmologyImage Processing Computer-AssistedHumansMedicinebusiness.industryRepeated measures designContact Lenses HydrophilicRefractive ErrorsContact lensOphthalmologyArtificial tearsmedicine.anatomical_structureTear meniscusOftalmologíaDry Eye SyndromesEyelidOphthalmic SolutionsbusinessTomography Optical CoherenceFollow-Up StudiesOptometryOptometry and Vision Science
researchProduct

Uveal effusion syndrome complicated by anterior ischemic optic neuropathy

1995

We report on a case of idiopathic uveal effusion syndrome complicated by AION. To our knowledge such an association hasn't been previously described. We suggest that scleral thickening caused obstruction of vortex veins followed by uveal effusion and compression of posterior ciliary arteries within their intrascleral tract, leading to AION. Nevertheless it can't be excluded that AION was the result of mechanical compression on ciliary vessels of optic disc by choroidal detachment. © 1996, Kluwer Academic Publishers. All rights reserved.

AtropineMydriaticsmedicine.medical_specialtyFundus OculiAnti-Inflammatory AgentsVisual AcuityIdiopathic uveal effusion syndromeDexamethasoneOptic neuropathyPregnenedionesPhysiology (medical)Ophthalmologymedicine.arteryHumansMedicineOptic Neuropathy IschemicFluorescein Angiographymedicine.diagnostic_testbusiness.industrySettore MED/30 - Malattie Apparato VisivoCiliary BodyRetinal DetachmentChoroid DiseasesSyndromeUveal DiseasesMiddle AgedFluorescein angiographymedicine.diseaseeye diseasesSensory SystemsScleral thickeningCiliary arteriesSurgeryOphthalmologyAnterior ischemic optic neuropathymedicine.anatomical_structureEffusionOptic nerveAnterior ischemic optic neuropathyFemalesense organsOphthalmic SolutionsbusinessOptic disc
researchProduct

Stability of tacrolimus ophthalmic solution

2017

Purpose The stability of 0.3-mg/mL tacrolimus ophthalmic solution at different storage temperatures was studied. Methods A sterile ophthalmic solution of 0.3 mg/mL tacrolimus was prepared in triplicate under aseptic conditions by diluting tacrolimus in eye drops. Three aliquots of this solution were transferred into polypropylene bottles and stored at 25, 2–8, or −15 to −25 °C. Samples were collected immediately after preparation and at selected time points and assayed in triplicate using high-performance liquid chromatography (HPLC). Samples were also visually examined for macroscopic changes. The 0.3-mg/mL tacrolimus solution was also exposed to acidic treatment and heat to force its degr…

Drug Storagemedicine.medical_treatmentAdministration Ophthalmicchemical and pharmacologic phenomena030226 pharmacology & pharmacyHigh-performance liquid chromatographyTacrolimus03 medical and health sciences0302 clinical medicineDrug StabilitymedicineHumansChromatography High Pressure LiquidPharmacologyChromatographyChemistryHealth PolicyTemperatureEye dropTacrolimusPharmaceutical Solutionssurgical procedures operativeOphthalmic solutionsAnesthesia030221 ophthalmology & optometryAseptic processingOphthalmic SolutionsImmunosuppressive AgentsAmerican Journal of Health-System Pharmacy
researchProduct

The efficacy and safety of unfixed and fixed combinations of latanoprost and other antiglaucoma medications.

2002

Adjunctive therapy for the management of glaucoma is commonly used. Unfixed combinations of the prostaglandin analog latanoprost and other glaucoma medications have been demonstrated to effectively lower intraocular pressure (IOP). The range of reported additional reductions in IOP compared to a monotherapy baseline are as follows: latanoprost-timolol (13-37%), latanoprost-pilocarpine 2% (7-14%), latanoprost and carbonic anhydrase inhibitors (15-24.1%), and latanoprost and dipivefrin (15-28%). There is a fixed combination of latanoprost (0.005%) and timolol (0.5%) that has been investigated in Phase III trials in Europe and the United States. In these trials, it was noted that the efficacy …

Intraocular pressureMydriaticsgenetic structuresCombination therapymedicine.medical_treatmentAdrenergic beta-AntagonistsTimololGlaucomachemistry.chemical_compoundMedicineHumansLatanoprostCarbonic Anhydrase InhibitorsAntihypertensive AgentsIntraocular PressureChemotherapyDipivefrinbusiness.industryGlaucomamedicine.diseaseeye diseasesOphthalmologyProstaglandin analogchemistryAnesthesiaProstaglandins F SyntheticLatanoprostDrug Therapy CombinationOcular Hypertensionsense organsOphthalmic SolutionsSafetybusinessmedicine.drugSurvey of ophthalmology
researchProduct

Update on topical carbonic anhydrase inhibitors

2001

Topical carbonic anhydrase inhibitors are a novel addition to the armamentarium of medical glaucoma treatment; dorzolamide has been available since 1995 and brinzolamide since 1998. They lower intraocular pressure by inhibiting carbonic anhydrase, a key enzyme for aqueous humor formation. Intraocular pressure-lowering activity of the substances appears to be the same and is similar to that of most other agents, but it does not reach the activity of the unselective beta-blocker timolol or the prostaglandin latanoprost. On concomitant treatment, additivity is reached with all other topical agents. A possible improvement of blood flow may offer an additional benefit, but its significance for t…

Intraocular pressuregenetic structuresBrinzolamideThiazinesGlaucomaTimololThiophenesPharmacologyEyeAqueous Humorchemistry.chemical_compoundDorzolamideCarbonic anhydrasemedicineHumansLatanoprostCarbonic Anhydrase InhibitorsAntihypertensive AgentsIntraocular PressureCarbonic Anhydraseschemistry.chemical_classificationSulfonamidesDose-Response Relationship Drugbiologybusiness.industryGlaucomaGeneral Medicinemedicine.diseaseeye diseasesOphthalmologyEnzymechemistryProstaglandins F Syntheticbiology.proteinLatanoprostsense organsOphthalmic SolutionsbusinessBlood Flow Velocitymedicine.drugCurrent Opinion in Ophthalmology
researchProduct

Efficacy and safety of combined diclofenac 0.1 % and gentamicin 0.3 eyedrops after phacoemulsification

1997

To study the efficacy of combined diclofenac 0.1% and gentamicin 0.3% (Digen) eyedrops to treat postoperative inflammation and prevent ocular infection in eyes having phacoemulsification.Department of Ophthalmology, University of Milan, San Paolo Hospital, Milan; Eye Clinic, University of Verona; and Department of Ophthalmology, University of Palermo, Italy.This double-masked, randomized, clinical trial comprised 90 patients; 45 received Digen and 45, gentamicin 0.3% eyedrops. The main outcome measure of the study was the reduction in signs and symptoms of inflammation, graded on a four-point scale. Also assessed were the presence of bacteria in the conjunctival swab and the proportion of p…

MaleDiclofenacAdministration Topicalmedicine.medical_treatmentEye diseaseEye Infections BacterialDiclofenacDouble-Blind MethodmedicineHumansAgedRetrospective StudiesAntibacterial agentAged 80 and overEndophthalmitisPhacoemulsificationbusiness.industryAnti-Inflammatory Agents Non-SteroidalAminoglycosideEye dropPhacoemulsificationMiddle Agedmedicine.diseaseSensory SystemsAnti-Bacterial AgentsClinical trialOphthalmologyTreatment OutcomeAnesthesiaDrug Therapy CombinationFemaleSurgeryGentamicinGentamicinsOphthalmic SolutionsSafetybusinessmedicine.drugJournal of Cataract and Refractive Surgery
researchProduct

Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocul…

2019

UNLABELLED: PRéCIS:: Noninferiority of efficacy was demonstrated for a preservative-free latanoprost-timolol fixed combination compared with a BAK-containing formulation at 84 days after treatment in patients with open-angle glaucoma or ocular hypertension. PURPOSE: The purpose of this study was to compare the effect on intraocular pressure and safety of preservative-free latanoprost-timolol fixed combination (T2347) to benzalkonium chloride-preserved latanoprost-timolol fixed combination in patients with open-angle glaucoma or ocular hypertension. METHODS: Phase III, randomized, parallel-group, investigator-masked study in 10 countries. A total of 242 patients aged 18 years or older with o…

MaleIntraocular pressuregenetic structures:Ciencias de la Salud::Oftalmología [Materias Investigacion]Ocular hypertensionGlaucomaLatanoprost-timololT2347 Study GroupOcular hypertensionlaw.invention0302 clinical medicineRandomized controlled triallawAged 80 and overMiddle AgedDrug CombinationsTreatment OutcomeTimololLatanoprostFemalemedicine.symptomLatanoprost/timololBenzalkonium CompoundsGlaucoma Open-Anglemedicine.drugAdultmedicine.medical_specialtyOpen angle glaucomaEquivalence Trials as Topic03 medical and health sciencesTonometry OcularOphthalmologymedicineHumansPreservative-freeAdverse effectAntihypertensive AgentsIntraocular PressureAgedbusiness.industryPreservatives PharmaceuticalGlaucomamedicine.diseaseeye diseasesOphthalmology030221 ophthalmology & optometryItchingOcular Hypertensionsense organsOphthalmic Solutionsbusiness030217 neurology & neurosurgery
researchProduct

Efficacy and safety of preoperative IOP reduction using a preservative-free fixed combination of dorzolamide/timolol eye drops versus oral acetazolam…

2017

Introduction To demonstrate that preoperative treatment for 28 days with topical dorzolamide/timolol is non-inferior (Δ = 4 mm Hg) to oral acetazolamide and topical dexamethasone (standard therapy) in terms of intraocular pressure (IOP) reduction 3 and 6 months after trabeculectomy in glaucoma patients. Materials and methods Sixty-two eyes undergoing trabeculectomy with mitomycin C were included in this monocentric prospective randomized controlled study. IOP change between baseline and 3 months post-op was defined as the primary efficacy variable. Secondary efficacy variables included the number of 5-fluorouracil (5-FU) injections, needlings, suture lyses, preoperative IOP change, hyperten…

MaleIntraocular pressuregenetic structuresEye DiseasesPhysiologymedicine.medical_treatmentTimololGlaucomalcsh:Medicine030204 cardiovascular system & hematologyDexamethasone0302 clinical medicineGlaucoma surgeryMedicine and Health SciencesMedicineTrabeculectomyProspective Studieslcsh:ScienceSulfonamidesMultidisciplinaryPharmaceuticsDorzolamide/TimololOphthalmic ProceduresMiddle AgedDrug CombinationsTreatment OutcomeResearch DesignAnesthesiaTimololFemaleFluorouracilAnatomyAcetazolamidemedicine.drugResearch Articlemedicine.medical_specialtyLysis (Medicine)Clinical Research DesignSurgical and Invasive Medical ProceduresTrabeculectomyThiophenesResearch and Analysis Methods03 medical and health sciencesMusculoskeletal System ProceduresDorzolamideDrug TherapyOcular SystemOphthalmologyTissue RepairPreoperative CareHumansAntihypertensive AgentsIntraocular PressureAgedbusiness.industrylcsh:RBiology and Life SciencesGlaucomamedicine.diseaseeye diseasesAcetazolamideOphthalmology030221 ophthalmology & optometryEyeslcsh:QOcular Hypertensionsense organsAdverse EventsOphthalmic SolutionsbusinessPhysiological ProcessesHeadPLoS ONE
researchProduct